《大行報告》匯豐研究上調比亞迪(01211.HK)目標價至407元 評級「買入」
匯豐研究發表報告,指出比亞迪(01211.HK)受惠於持續強勁的需求及供應增長,其5月份新能源車銷量達破紀錄的11.5萬輛,按年增長1.48倍,按月升8%。該行料未來幾個月銷量將進一步提升,主要由於其產品定位具競爭力,以及5月份推出新產品如比亞迪「海豹」或Denza D9,並於今年下半年至明年陸續推出包括海洋系列PHEV車型在內的產品,與新的高端品牌。
此外,該行認爲比亞迪的產品週期加速,產品定價範圍更高,可能進一步推動銷量及毛利率。該行維持對其「買入」評級,H股目標價由373元上調至407元,預期公司強勁的新能源汽車產品週期及電池技術,長遠而言有利提升盈利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.